TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01910662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuberculin PPD
Description: Tuberculin PPD will be administered in Part B Cohort 2 on Day 1 as single ID injection of 2TU (0.04 microg/mL) in each forearm. In Part C Cohort 2 PPD will be administered on Day 1 as a single ID injection of 2TU. On day 3, if the induration is 6 mm or more; 2 ID injections of 2 TU will be administered on Day 29 in Part B Cohort 2 and 1injection of 2TU on Day 29 in Part C Cohort 2. On day 3, if the induration is less than 6 mm, subject will be re-challenged with 10 TU (0.04 microg/mL) PPD followed by 2 ID injections of 10 TU on Day 29 in Part B Cohort 2 or 1 ID injection of 10TU on Day 29 in Part C Cohort 2.
Study: NCT02740582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02424786

Intervention type: OTHER
Group type: OTHER
Intervention: STOPP/START criteria
Description: Evaluation of medication lists
Study: NCT02731768

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively.They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support-enhanced
Description: Participants will receive the same intervention components as the Standard group.Participants will also be provided with two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
Study: NCT01606722

Intervention type: DRUG
Intervention: Darunavir/ritonavir
Description: Darunavir/ritonavir (800/100 mg once daily) monotherapy
Study: NCT02731768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Zip

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Zip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital body weight scale

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital body weight scale
Study: NCT01460836

Intervention type: DRUG
Intervention: Tobramycin solution for inhalation

Intervention type: DRUG
Intervention: Aztreonam lysine for inhalation
Study: NCT02628223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser Trabeculoplasty
Description: The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser Trabeculoplasty
Description: The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neodymium:Yttrium Aluminum Garnet (YAG) laser
Description: The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neodymium:Yttrium Aluminum Garnet (YAG) laser
Description: The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
Study: NCT02214758

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition and oral health interventions
Description: On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition and oral health interventions
Description: On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.
Study: NCT00865501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: 25mg per oral once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03419247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood will be taken by a needle from a vein.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Archival tumor tissue collection
Description: A sample of tumor tissue that was taken by biopsy or surgery before agreeing to take part in this study will be collected.
Study: NCT01791062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYTOP®
Description: HYTOP® will be implanted once during surgery.
Study: NCT02729987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WorkGuru
Description: A multi-modal stress management intervention accessed over 8 weeks, incorporates CBT, positive psychology and Mindfulness. Delivered via the internet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WorkGuru
Description: A multi-modal stress management intervention accessed over 8 weeks, incorporates CBT, positive psychology and Mindfulness. Delivered via the internet.
Study: NCT04005222

Intervention type: DRUG
Group type: OTHER
Intervention: SELENIUM
Description: Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium supplementation.

Intervention type: DRUG
Group type: OTHER
Intervention: MELATONIN
Description: Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.
Study: NCT05291195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-device group
Description: After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the laser-device groups, the adjuvant treatment approaches were performed either by means of photodynamic therapy (HELBO, Photodynamic Systems GmbH) or high power diode laser (940nm, Biolase ® Technology, CA, USA). Performing photodynamic therapy the root canals were filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Germany) for 2 min following irradiation of diode laser (HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW)) for 60 s. Performing only diode laser the root canals were be irrigated with a diode laser (λ = 940 maximal power 10W) for 60 s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential Oil
Description: After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the EO group, the adjuvant treatment approaches were performed either by means of essential oil (Cymbopogon martinii and Thymus vulgaris, Herba oils, Herba d.o.o, Belgrade, Serbia)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite group
Description: Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite group
Description: Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite group
Description: Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
Study: NCT02235922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task training
Description: The dual task training consisted of individuals subjected to a multicomponent exercise program associated to cognitive tasks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional training
Description: The conventional training consisted of individuals subjected to a multicomponent exercise program.
Study: NCT01289535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample of 7 ml
Study: NCT01812746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIND-014
Study: NCT02213991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy using Intrabeam®
Description: Operation day~1. Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity.~2. Purse string suture pulles up tissues and wraps up the applicator.~3. Intraoperative radiotherapy using Intrabeam® (20Gy) is followed.~4. After IORT, applicator was out of the operative field, and usual wound closure will be done.~   * Postoperative period~     * Chemotherapy WBRT (46 Gy) for 4\~5 weeks~    * Endocrine therapy or target therapy
Study: NCT03357445

Intervention type: OTHER
Group type: OTHER
Intervention: Avantage Reload cup
Description: Patients receiving the Avantage Reload acetabular cup in total hip arthroplasty

Intervention type: OTHER
Group type: OTHER
Intervention: Avantage Reload cup
Description: Patients receiving the Avantage Reload acetabular cup in total hip arthroplasty
Study: NCT01857115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT03375957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201
Description: two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201
Description: two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATx201 Placebo Gel
Description: two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms
Study: NCT02287844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: XOS
Description: 5 g of XOS everyday for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INU-XOS
Description: 1 g of XOS and 3 g of inulin everyday for 4 weeks.
Study: NCT01857115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT04414202

Intervention type: PROCEDURE
Intervention: tumorectomy with axillary dissection (sentinel lymph node)
Description: All patients will have local excision of the primary tumor following appropriate clinical work-up. Surgery will be done according to usual local practice with a complete excision of the tumor. The aim of the local excision should be to achieve a minimum free margin of 2 mm whilst maintaining a good cosmetic outcome.

Intervention type: RADIATION
Intervention: per-operative partial irradiation
Description: 20 Gy of per-operative partial irradiation at the tumor site during the surgery
Study: NCT02287844

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 6.64 g of maltodextrins everyday for 4 weeks.
Study: NCT02726360

Intervention type: BEHAVIORAL
Intervention: survey
Description: The ILR Scale, a non-English language proficiency self-assessment.
Study: NCT02415218

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mucosal cell sheet transplantation
Description: The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
Study: NCT02475213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: enoblituzumab is administered by IV infusion once per week for up to 51 doses.
Study: NCT02726360

Intervention type: BEHAVIORAL
Intervention: Audio record
Description: Audio record the initial visits between patients and their treating physician

Intervention type: BEHAVIORAL
Intervention: Audio record
Description: Audio record the initial visits between patients and their treating physician
Study: NCT02240628

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine/tetracaine transdermal patch
Description: All patients in arm 1 and arm 2 will receive the Synera Patch.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine/tetracaine transdermal patch
Description: All patients in arm 1 and arm 2 will receive the Synera Patch.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients in arm 2 will receive Saline with the Propofol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients in arm 1 will receive Lidocaine with the Propofol.
Study: NCT03121716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-platinum
Description: cis-platinum
Study: NCT00318188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standardized reeducation and readaptation program
Study: NCT01408654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Companionship
Description: Peer companionship is provided at least four times per month over two years in the form of friendly visiting, supportive phone calls, and some instrumental support.
Study: NCT04029545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PN40082
Description: 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PN40082
Description: 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PN40082
Description: 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
Study: NCT01963663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 1000 mg daily in two divided doses of 500 mg tablets
Study: NCT02410369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-588410
Description: Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of S-588410.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
Study: NCT03450889

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Patients will undergo surveillance colonoscopies, with intervals of 1 or 2 years depending on the amount and type of polyps resected during last colonoscopy.~In case patients underwent subtotal colectomy, the term 'colonoscopy' should be replaced with 'sigmoidoscopy'.
Study: NCT02717546

Intervention type: DEVICE
Intervention: Zimmer MotionLoc Screw
Description: Patients with distal tibia fractures (AO 43-A and C) requiring surgical intervention eligible for locked plating.
Study: NCT02475213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: enoblituzumab is administered by IV infusion once per week for up to 51 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: enoblituzumab is administered by IV infusion once per week for up to 51 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: enoblituzumab is administered by IV infusion once per week for up to 51 doses.
Study: NCT00974779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCO1100 dialyzer
Description: Thrice weekly dialysis using the HCO1100 dialyzer for 4.5h, 2 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: regular dialysis polyamide
Description: Continuation of the regular hemodialysis using polyamide high-flux hemodialysers
Study: NCT03117933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablet, 100mg and 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablet, 100mg and 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Tablet 15mg and 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous (IV)
Study: NCT01237548

Intervention type: OTHER
Intervention: Smoking Narghile for 30 min
Description: No Other intervention will be used
Study: NCT04116034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alfapump DSR system
Description: Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
Study: NCT05712031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of 1 Nucleoss T4 dental implants in posterior mandible
Description: Nucleoss T4 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of 1 Nucleoss T5 dental implants in posterior mandible
Description: Nucleoss T5 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of 2 Nucleoss T4 dental implants posterior mandible
Description: 2 freestanding Nucleoss T4 dental implants is used to support 3 unit fixed partial dentures
Study: NCT05090345

Intervention type: OTHER
Intervention: Biorepository Trial
Description: participating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.
Study: NCT04095416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACE compression wrap
Description: Bilateral lower extremity ACE compression wraps
Study: NCT00816972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine 2.5 mg
Description: Desloratadine 2.5 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 2.5 mg
Description: Desloratadine 2.5 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 2.5 mg
Description: Desloratadine 2.5 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin 2.5 mg
Description: Oxybutynin 2.5 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin 2.5 mg
Description: Oxybutynin 2.5 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin 2.5 mg
Description: Oxybutynin 2.5 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Desloratadine 2.5 mg
Description: Placebo BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Desloratadine 2.5 mg
Description: Placebo BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Oxybutynin 2.5 mg
Description: Placebo BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oxybutynin 2.5 mg
Description: Placebo BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Oxybutynin 2.5 mg
Description: Placebo BID
Study: NCT03763279

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Triclosan-coated barbed suture
Description: Use of Triclosan-coated Polydioxanone barbed suture

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Triclosan-coated monofilament suture
Description: Use of Triclosan-coated Polydioxanone monofilament suture

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Monofilament suture
Description: Use of Polydioxanone monofilament suture
Study: NCT00609128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olopatadine
Description: olopatadine one drop in one eye for one week
Study: NCT00994565

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitoring and distance counseling
Description: The physical activity monitoring and distance counseling concept combines the use of a personal activity monitor with web-based tailored physical activity advice. Users can interactively plan and evaluate their own activity advice based on their actual PA scores and their PA preferences and goals.
Study: NCT02640612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501
Study: NCT01737164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Study: NCT02884180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: A dose of 24 mg dexamethasone given after start of anaesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline isotonic
Description: A dose of 6 ml of isotonic saline given after start of anaesthesia